Trefoil Therapeutics Inc. has reported promising data from a phase II trial suggesting its engineered version of fibroblast growth factor 1, TTHX-1114, may speed and improve recovery of patients with Fuchs endothelial corneal dystrophy who are undergoing a surgical procedure called Descemet stripping only.
Researchers at the Diabetes Institute of the University of Washington and the University of Copenhagen have implicated the brain in the ability of intracranial injections of fibroblast growth factor 1 (FGF1) to restore blood sugar control to diabetic animals for long periods of time.